» Articles » PMID: 28748498

The Value of Explicitly Emulating a Target Trial when Using Real World Evidence: an Application to Colorectal Cancer Screening

Overview
Journal Eur J Epidemiol
Specialty Public Health
Date 2017 Jul 28
PMID 28748498
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

Observational analyses for causal inference often rely on real world data collected for purposes other than research. A frequent goal of these observational analyses is to use the data to emulate a hypothetical randomized experiment, i.e., the target trial, that mimics the design features of a true experiment, including a clear definition of time zero with synchronization of treatment assignment and determination of eligibility. We review a recent observational analysis that explicitly emulated a target trial of screening colonoscopy using insurance claims from U.S. Medicare. We then compare this explicit emulation with alternative, simpler observational analyses that do not synchronize treatment assignment and eligibility determination at time zero and/or do not allow for repeated eligibility. This empirical comparison suggests that lack of an explicit emulation of the target trial leads to biased estimates, and shows that allowing for repeated eligibility increases the statistical efficiency of the estimates.

Citing Articles

Effectiveness of treat-to-target cholesterol-lowering interventions on cardiovascular disease and all-cause mortality risk in the community-dwelling population: a target trial emulation.

Yang Z, Deng Q, Hao Y, Yang N, Han L, Jia P Nat Commun. 2024; 15(1):9922.

PMID: 39548082 PMC: 11568141. DOI: 10.1038/s41467-024-54078-4.


Conducting observational analyses with the target trial emulation approach: a methodological systematic review.

Simon-Tillaux N, Martin G, Hajage D, Scheifer C, Beydon M, Dechartres A BMJ Open. 2024; 14(11):e086595.

PMID: 39532374 PMC: 11574403. DOI: 10.1136/bmjopen-2024-086595.


Overall survival after CDK4/6 inhibitor dose reduction in women with metastatic breast cancer.

Bjerrum A, Henriksen A, Knoop A, Berg T, Tuxen I, Lassen U BJC Rep. 2024; 2(1):82.

PMID: 39516687 PMC: 11523986. DOI: 10.1038/s44276-024-00108-z.


Designing Rigorous and Efficient Clinical Utility Studies for Early Detection Biomarkers.

Zheng Y, Wagner P, Singal A, Hanash S, Srivastava S, Huang Y Cancer Epidemiol Biomarkers Prev. 2024; 33(9):1150-1157.

PMID: 39223980 PMC: 11534000. DOI: 10.1158/1055-9965.EPI-23-1594.


Bias due to coarsening of time intervals in the inference for the effectiveness of colorectal cancer screening.

Karmakar B, Zauber A, Hahn A, Lau Y, Doubeni C, Joffe M Int J Epidemiol. 2024; 53(4).

PMID: 39002174 PMC: 11246168. DOI: 10.1093/ije/dyae096.


References
1.
Smith R, Andrews K, Brooks D, DeSantis C, Fedewa S, Lortet-Tieulent J . Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2016; 66(2):96-114. DOI: 10.3322/caac.21336. View

2.
Hernan M, Robins J . Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. Am J Epidemiol. 2016; 183(8):758-64. PMC: 4832051. DOI: 10.1093/aje/kwv254. View

3.
Garcia-Albeniz X, Hsu J, Bretthauer M, Hernan M . Screening Colonoscopy to Prevent Colorectal Cancer Among Medicare Beneficiaries Aged 70 to 79 Years. Ann Intern Med. 2017; 166(10):758-759. DOI: 10.7326/L17-0138. View

4.
Stock D, Paszat L, Rabeneck L . Colorectal cancer mortality reduction is associated with having at least 1 colonoscopy within the previous 10 years among a population-wide cohort of screening age. Gastrointest Endosc. 2016; 84(1):133-41. DOI: 10.1016/j.gie.2015.12.035. View

5.
Hernan M, Sauer B, Hernandez-Diaz S, Platt R, Shrier I . Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016; 79:70-75. PMC: 5124536. DOI: 10.1016/j.jclinepi.2016.04.014. View